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Background: Extracorporeal photopheresis (ECP) is an innovative therapy. It 
excels in its clinical benefit and low toxicity for patients with cutaneous T-cell 
lymphomas (CTCL) in advanced stages. ECP is available at the “Instituto 
Nacional de Cancerología” (National Cancer Institute) in Bogotá, Colombia since 
2016. This being currently the only device available in the country. The objective 
of this study is: to generate real-world evidence by describing the results of 
patients treated with ECP through a descriptive analysis of population 
characteristics, showcase the results of the treatment in terms of response and 
survival, and associated complications regarding said treatment. This is a case-
series descriptive study, which included patients diagnosed with erythrodermic 
MF and SS treated with extracorporeal photopheresis following institutional 
protocols. 
  
Results: 616 ECP sessions were performed in 17 patients. Overall response rate 
(ORR) was obtained in sixteen patients (64,7%), with a partial response (PR) in 
nine patients (52,9%), and complete response (CR) in two patients (11.8%). 
Response rates improved when combined with adjunctive therapies. The median 
mSWAT reduction was 98 points and the median VASP reduction was 4 points 
on the analogous visual scale. Median survival for the entire group measured 
from the onset of treatment until death was not reached (95% CI: 859-NA). The 
12-month survival probability was 82% (95% CI: 66-100%). Complications 
occurred in 2% of performed sessions, most related to difficulties in the venous 
access.  
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Conclusion: ECP should be considered as first-line therapy for erythrodermic 
MF/SS based not only on its efficiency and excellent side effect profile but also 
on the significant improvement of the symptoms. 
   
Abbreviations  
CTCL: Cutaneous T-cell lymphomas  
SS: Sézary Syndrome  
MF: Mycosis Fungoides 
ECP: Extracorporeal photopheresis  
ORR: Overall response rate  
PR: Partial response  
CR: Complete response  
mSWAT: Severity Weighted Assessment Tool  
VASP: Visual Analogal Scale Pruritus  
EORTC: European Organization for Cancer Research and Treatment  
TCR: T-cell receptor 
SD: Standard deviation 
IQR: Interquartile range 
CHOP: chemotherapy combination with cyclophosphamide, doxorubicin 
hydrochloride, vincristine sulfate, and prednisone 
IFN: Interferon alfa 
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Extracorporeal photopheresis (ECP) was described in 1987 as a potential 
therapy for patients with cutaneous T-cell lymphomas (CTCL) in advanced 
stages [1]. In 1988, the FDA approved extracorporeal photopheresis for the 
treatment of Sézary Syndrome (SS) and erythrodermic Mycosis Fungoides (MF) 
[1].  
 
ECP is a therapeutic method by which the patient's blood is obtained through a 
peripheral mean, such as a vein, to isolate the leukocytes from the plasma and 
non-nucleated cells (platelets and erythrocytes)- this process is known as 
apheresis. Through special devices, these leukocytes are exposed to a 
photosensitizing agent (8-methoxy psoralen) to be subsequently subjected to 
UV-A radiation (329-400nm) and reinfused into the patient [2]. 
3	
The effect produced by UV-A radiation within the psoralen-exposed DNA, is a 
crosslinking of the pyrimidine bases, therefore leading the cell to apoptosis [3].  
Despite its excellent safety profile and efficacy, the exact mechanism of action of 
ECP is still under exploration. Based on clinical observations, it is believed to 
induce an immune response to the malignant T cell clone [1]. 
 
Cutaneous lymphomas are a heterogeneous group of Non-Hodgkin lymphomas. 
With a global incidence of 10.3 per million[6] people annually it represents 19% 
of extranodal lymphomas [4]. Cutaneous T-cell lymphomas, (which are the most 
frequent type of lymphoma) account for 75-80% of all cutaneous lymphomas [5]. 
 
Mycosis fungoides (MF) is the most frequent variant of CTCL (60%), with an 
estimated incidence of 5.6 per million people [4-6]. It is staged according to the 
extent of skin involved (patches, plaques, or tumors). Also the nodal, blood, and 
visceral compromise [7]. Sézary syndrome (SS) is a rare leukemic form of CTCL, 
with an estimated incidence of 0.1 per million people in the USA [8]. SS is 
traditionally defined as a triad of a very itchy erythroderma, generalized 
lymphadenopathy, and the presence of neoplastic T-cell clones with cerebriform 
nuclei (Sézary cells) in the skin, lymph nodes, and peripheral blood [5]. 
 
MF and SS are classified according to the TNMB of the International Society for 
Cutaneous Lymphomas (ISCL) and the group of cutaneous lymphomas of the 
European Organization for Cancer Research and Treatment (EORTC) [9]. In this 
classification, cutaneous lymphomas are divided into two large groups: initial 
stages (IA, IB, IIA) and advanced stages (IIB, IIIA, IIIB, IVA, IVB). 
From stage IIIA (erythroderma), the median survival ranges from 1.4 to 4.7 years. 
Disease-associated survival ranges from 18% to 45% at 5 years and the risk of 
disease progression ranges from 53% to 82% at 5 years [10]. Regarding SS, the 
prognosis is substandard, with a 5-year survival rate of 24% [11]. 
 
Globally, there are marked differences related to the therapeutic approaches. 
Mainly, given the low prevalence of the disease and the scarce evidence 
available. [12]. 
The results of the treatment with systemic chemotherapy are unsatisfactory, with 
low response rates and high toxicity [14, 15]. This treatment option is usually 
reserved for patients with refractory disease. On their own targeted therapies 
have an ORR (Overall Response Rate) ranging from 30 to 67%. Furthermore, 
complete responses do not exceed 41% [13].  
 
Currently, no clinical trials are showing the efficiency of ECP as monotherapy in 
the treatment of MF/SS. Nonetheless, international organizations propose it as 
the first-second treatment in advanced stages of the disease.  
Edelson et al. reported a response rate of 73% in its original publication[1]. Since 
then, several case series and retrospective studies have been published 
confirming the efficiency of ECP. The effectiveness has been seen especially in 
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patients with erythrodermic MF and SS, displaying response rates of around 60% 
[16]. 
 
Since 2016, the Instituto Nacional de Cancerología (National Cancer Institute), 
holds the only available ECP equipment in the country.  
To our knowledge, there is currently no data of studies made with Latin-American 
populations, moreover, the results of EPC in our target population are unknown. 
To date, 17 patients diagnosed with erythrodermic mycosis fungoides and 
Sézary Syndrome have been treated. In a prospective register of the patients 
treated using EPC, there is a record of more than 600 sessions. 
The objective of this study is: to generate real-world evidence, describing the 
results of patients treated with ECP in our country through a descriptive analysis 
of the population characteristics, the results of the treatment in terms of response 
and survival, and the complications associated with said treatment. Additionally, 
the operational characteristics of apheresis procedures will be described. 
 
In this manner, an interest in the biological and clinical advantages of EPC, and 









The study at hand is a Case-series descriptive study. 
 
This study included patients that exceeded 18 years of age and were diagnosed 
with erythrodermic MF and SS further treated with extracorporeal photopheresis, 
following the established institutional protocols. The treatment consisted of two 
sessions on consecutive days, every two weeks for at least three months. This 
was followed by two sessions on consecutive days, every four weeks in the 
THERAKOS™ CELLEX™ Photopheresis System (Therakos, Exton, PA, U.S.A.). 
Patients who received at least one apheresis session between October 1st, 2016 
and April 30th, 2020 were registered consecutively. The inclusion criteria of the 
participants were: the patient must be more than 18 years of age, a confirmed 
diagnosis of MF or SS, the patient must have complete data in the clinical chart 
regarding the response to treatment, and patients under follow-up at the National 
Cancer Institute. 
The information was taken from the digital medical records and the data of each 
apheresis procedure performed. Variables included: sociodemographic 
information (date of birth, sex, affiliation, education, and origin), clinical and 
treatment information (date of diagnosis, date of onset of extracorporeal 
photopheresis, response to extracorporeal photopheresis, date of death or last 





Descriptive analysis was performed to observe the frequency of presentation of 
the variables under study. It was not intended to establish any kind of statistical 
inference. Measurements were calculated depending on the type of variable. For 
the definition of the sociodemographic, clinical-pathological characteristics, and 
characterization of the treatment, quantitative and qualitative variables were 
analyzed. 
By building tables of frequency distribution nominal and ordinal variables were 
described by frequencies and percentages. Continuous quantitative variables 
were described by mean and standard deviation if they meet the normality 
criteria. Otherwise, they were described by the median and the limits of the 
interquartile range. 
The estimation of global and event-free survival was calculated using the Kaplan-
Meier limit product method.  
All the information was handled completely anonymously, coding the 
identification data of the patients and assigning each one a unique registration 
number that would identify them throughout the study.  
Descriptive statistics, survival analysis, and univariate and multivariate analysis 




This study has been designed in coherence with the ethical guidelines and 
principles for research in human beings. Explicitly, the demands of international 
documents such as the Declaration of Helsinki and the Belmont Report were fully 
embraced throughout the study. National documents such as resolution 8430 of 
1993 were also used as a guideline. This study is considered risk-free 








Description of Study subjects 
 
Seventeen patients were included, of which ten (58.8%) were male. The median 
age was 49 years (32-72 IQR 22), being 60.5 years in men and 43 years in 
women. This difference was statistically significant (p value= 0.019, Mann-
Whitney U test). Nine patients (52.9%) had Sézary Syndrome, eight patients 
(47.1%) had Mycosis fungoides. Six patients (35.3%) had foliculotropic mycosis 
fungoides, and two patients (11.8%) had hyperpigmented (lichenoid) mycosis 
fungoides. Distribution of diagnosis by sex is presented in Table 1. 
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Immunophenotype was CD4+ in fifteen cases (88,2%) and CD8+ only in two 
cases (11.8%). 
Other population characteristics are presented in Table 2. 
 
Initial clinical presentation 
 
Stage information before starting ECP treatment was available in all patients. 
Eight patients (47.05%) were in stage III and four patients (23.53%) were in 
stage IV.  
A total of 16 patients (94%) were classified as T4 (erythroderma), at the time of 
the beginning of treatment with ECP. One patient was classified as T2. A young 
patient with a diagnosis of hyperpigmented MF for more than 10 years, in whom 
multiple topical and systemic treatments were administered with the persistence 
of symptoms. The staging data and TNMB distribution is presented in Figure 1. 
 
The detection of Sézary cells was performed by morphological and 
immunohistochemical analysis. The average number of circulating Sézary cells 
was 15.62 (SD 20.91). Differences in the number of circulating cells per stage 
were identified. 
These differences were statistically significant (ANOVA F 6.0054, p-value= 
0.0085). The difference was found to be significant between stage IVB and IB 
patients (p-value 0.004, Tukey's test), but there was no difference in any other 
group. This data is displayed in Figure 2. 
 
 
T-cell receptor (TCR) gene rearrangements were available in only a limited 
number of patients. Blood samples were available in five patients (29.4%), being 
positive in four of them (23.5%). In skin biopsy samples, it was performed in nine 





Of the seventeen patients, sixteen (94.11%) received skin-directed therapies. 
The median number of skin-directed therapies was two (0-3, IQR=1). Sixteen 
patients (94.11%) received topical corticosteroids. Twelve patients (70.58%) 
received PUVA, only one patient (5.88%) received UVB, and no patients 
received topical retinoid treatment. 
 
All patients received systemic therapy. The average number of systemic lines 
before the start of ECP was 2.47 (SD: 1.17). Ten patients (58.82%) 
received interferon, seven patients (41.17%) received methotrexate. six patients 
(35.29%) received CHOP chemotherapy, five patients (29.41%) 
received liposomal doxorubicin, four patients (23.52%) received vorinostat, four 
patients (23.52%) received pralatrexate, and seven patients (41.17%) received 
other treatment. Results are presented in Figure 3. 
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Nine patients (52.94%) received systemic therapy associated with ECP; five 
patients (29.41%) received methotrexate, three patients (17.64) 
received interferon, one patient (5.88%) received vorinostat, and two patients 
(11.76) received another treatment. 
 
ECP therapy results 
In total, 616 extracorporeal photopheresis sessions were performed on 17 
patients. The median number of sessions performed per patient was 38 (2-77, 
IQR: 75) (average 36.2). Figure 4 shows the number of sessions received per 
patient. 
 
The mean duration of the procedure for the whole group was 2.12 hours (SD: 
0.39). The average duration of the procedure through the central venous line was 
1.47 hours and through the peripheral venous line was 2.18 hours. The mean 
treatment volume was 161 ml (SD: 32). The mean photoactivation time was 26.5 
min (SD: 6.8). The mean photosensitizing agent volume was 2.78 ml (SD: 0.54).  
Adverse reactions occurred in 2% of the performed sessions (12 sessions), of 
which, the most frequent complication was related to difficulties in venous access 
(10 sessions), followed by technical failure (1 session) and fever (1 session).  
The characteristics of the sessions discriminated by patient are presented in 
Table 4. 
 
The median time to the onset of treatment from diagnosis was 359 days (3-2395, 
IQR 636). 
 
The median mSWAT (modified Severity Weighted Assessment Tool - method of 
choice for assessing skin tumor burden in both mycosis fungoides and Sézary 
syndrome) before ECP treatment was 178 (70-400 IQR: 100). The median 
mSWAT at last patient contact was 80 (0-400 IQR: 92). The median reduction in 
mSWAT for the whole population was 98 points, as presented in Table 5. The 
Wilcoxon sum test for paired data shows that this difference was statistically 
significant (p value= 0.0075). mSWAT changes discriminated by treatment 
response rates are shown in Figure 5. 
 
The median VASP (pruritus assessment scale) before ECP treatment was 10 (0-
10 IQR: 2). The median VASP at last patient contact was 6 (0-10 IQR: 96). The 
median reduction in VASP for the whole population was 4 points on the 
analogous visual scale, as shown in Table 6. The Wilcoxon sum test for paired 
data shows that this difference was statistically significant (p value= 0.0037). 
VASP changes discriminated by treatment response rates are shown in Figure 6. 
 
Following ECP therapy, the overall response rate (ORR) was obtained in sixteen 
patients (64,7%), with a partial response (PR) in nine patients (52,9%), and 
complete response (CR) in two patients (11.8%). Only one patient (5.9%) had 
progression. All patients who obtained a complete response received combined 
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treatment. Of the nine patients who obtained a partial response, six received 
combined treatment. Of the five patients with stable disease, only one received 
combined treatment. The patient who had disease progression did not receive 
combined treatment. The response categories with combined treatment are 
shown in Figure 7. 
 
At the time this study was closed, eight patients (47.6%) were still ongoing 
therapy, and five deaths (29.4%) were reported. Death causes were: sepsis in 
two patients, neuro infection in one patient, COVID-19 in one patient, and 
unknown cause of death in one patient.  
Median survival for the entire group measured from the onset of treatment until 
death was not reached (95% CI: 859-NA). The 12-month survival probability was 




Mycosis Fungoides (MF) and Sézary Syndrome (SS) account for the majority of 
cutaneous T-cell lymphomas (CTCL). These are rare entities and have variable 
clinical presentations [17]. Treatment options for advanced-stage MF and SS are 
limited, generally unsatisfactory, with low response rates and high toxicity for the 
patient [14]. 
The therapeutic strategies for CTCL adopted in the different cancer centers 
around the world are influenced by consensus, institutional preference, and the 
availability of treatment modalities. There is no available data on the impact that 
this variability of treatments may have on survival [7].  
In 2017, Quaglino et. al published a multicenter retrospective study that included 
853 patients from 21 specialized centers (14 European, 4 American, 1 Australian, 
1 Brazilian, and 1 Japanese). This study showed that there is a great 
heterogeneity of treatment in mycosis fungoides in advanced stages and Sézary 
Syndrome in different institutions worldwide. The data found in this study 
revealed that chemotherapy as the first line of treatment is associated with an 
increased risk of death. Moreover, extracorporeal photopheresis is the most 
frequently used therapy as first-line treatment in SS or erythrodermic MF (stage 
III and IVA1) [18]. 
The mechanism of action of ECP in cutaneous T-cell lymphomas is not 
established. Theories supporting the therapeutic effect propose the induction of 
an immune response to the malignant T-cell clone. Although less than 10% of the 
total leukocyte population is treated during one procedure, the reduction in 
malignant T cells is usually greater than this percentage in peripheral blood [6]. 
This involves the following events: (1) induction of malignant T cell apoptosis, (2) 
conversion of circulating monocytes to immature dendritic cells, (3) presentation 
of dendritic cells (exposed to tumor cells) to cytotoxic T cells. and (4) expansion 
of a cytotoxic T cell population against the malignant T cell clone [19]. 
The results observed in this case series are comparable with those published to 
date. In our study, men were more commonly affected than women, as reported 
in other studies (incidence rate ratio [IRR] = 1.6) [8, 20]. The median age of our 
9	
study sample was 49 years (32-72 IQR 22), being 60.5 years in males and 43 
years in females. Incidence rates reported for MF are similar among males and 
females at ages younger than 40 years, but notably higher among males at older 
ages [8].  
Based on different consensus recommendations worldwide [9, 21, 22], most 
patients treated with ECP in our study were erythrodermic MF (stage III, T4N0-
2M0B0-1) and SS (stage IVA1 or 2, T4N0-3M0B2). Although current guidelines 
for non-Hodgkin lymphoma do not recommend ECP as primary treatment in 
early-stage MF (IA, IB, IIA), in patients with the treatment-refractory disease, 
ECP is listed as a systemic treatment option[23]. 
Differences in the number of circulating Sézary cells per stage were identified. 
These differences were found to be significant between stage IVB and IB 
patients. This would be supported by current NCCN guidelines for Primary 
Cutaneous Lymphomas, which do recommend ECP as one of the primary 
treatments for SS and erythrodermic MF with B1 blood-stage but not for patients 
with erythrodermic MF with no evidence of blood involvement. Also, ECP is 
recommended in patients with stage IA, IB, and IIA disease and B1 blood 
involvement or those with the treatment-refractory disease [23], as mentioned 
above. 
Although the identification of clonal TCR gene rearrangement has no prognostic 
value, it was helpful to determine clinical staging and assess relapsed or residual 
disease in some patients. 
There is no evidence to suggest that topical therapies have a significant impact 
on the course of the disease for the advanced stages of MF/SS, although skin 
directed therapies can alleviate skin symptoms such as pain and pruritus, and 
most patients will require intermittent topical treatments, especially topical 
steroids [24]. Most of our patients (94.11%) received skin directed therapies 
previous to ECP. Phototherapy in the early stages of MF produces high complete 
remission rates, 70.58% of our patients had received the previous PUVA, and 
5.88% UVB. However, patients with erythrodermic MF/SS are often intolerant of 
phototherapy due to aggravation of pruritus [24].   
Response to systemic treatment of erythrodermic MF and SS is deficient. As 
there are currently no effective systemic therapies with long-lasting responses. 
The most widely described include interferon alfa with a dose-dependent 
response and in combination with systemic retinoids or methotrexate [25, 26]. In 
our study, all patients received systemic therapy. The average number of 
systemic lines before the start of ECP was 2.47 (SD: 1.17). The most frequent 
systemic therapies were interferon, methotrexate, and CHOP chemotherapy. The 
results of the treatment with systemic chemotherapy are unsatisfactory, with low 
response rates and high toxicity [14, 15]. It is usually a therapy that is reserved 
for patients with refractory disease, with a more palliative rather than curative 
use. 
In their original publication, Edelson et al. Reported a response rate of 72.9% [1]. 
Since then, several case series and retrospective studies have been published 
confirming the efficacy of photopheresis, especially in patients with erythrodermic 
MF and SS, showing an ORR (overall response rate) around 60-63% and a 
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complete response rate around 20% [16, 27]. Results in our study are similar to 
those reported, with an ORR of 64,7%, partial response (PR) of 52,9%, and 
complete response (CR) of 11.8%. All patients who obtained a complete 
response received combined treatment and most of the patients who obtained a 
partial response received combined treatment. There is evidence to support 
higher response rates when ECP is combined with adjunctive therapies. Duvic et 
al, reported response rates of 40% in ECP monotherapy vs. 57% in combination 
of ECP plus IFN alfa, bexarotene, or GM- CSF in a group of patients with stage 
III/IV MF/SS [28]. In a retrospective review of 98 patients with SS treated with 
ECP combined with systemic IFN gamma, IFN alfa, GM-CSF, systemic retinoids, 
response rates of 75% were reported with a CR of 30% [29]. In a review of 34 
patients with SS treated with ECP, IFN, and bexarotene, 88.2% of patients 
responded to the combined therapy, with a CR in 32.4% of patients [30]. The 
combination of ECP, IFN alfa/gamma, and bexarotene may lead to the highest 
response rates in patients with SS. 
The reduction in the median of the mSWAT for the entire population was 98 
points, being up to 400 points for the patients with complete response, with a 
median number of sessions performed per patient of 38. Edelson reported an 
average reduction of 64% of skin involvement after 22 weeks of treatment. These 
findings confirm the need for treatment as recommended by a minimum of 6 
months [19]. 
The greatest impact on the quality of life of patients with MF / SS is pruritus, with 
limited options in pharmacological treatment that leads to a faulty response. All 
patients in our study presented a decrease in pruritus, with a median reduction in 
the visual analog scale (VASP) of 4 points. 
In this study, median survival was not reached. The 12-month survival probability 
was 82% (95% CI: 66-100%). A follow-up analysis of the Edelson cohort 
published in 1992 showed a median survival of 60 months for patients who 
received ECP [31]. Similar median survivals were reported in other cohorts [32, 
33]. The survival of patients with erythrodermic MF/SS on ECP remains to be 
confirmed with a prospective study. 
ECP is usually well tolerated. Adverse effects reported are mostly related to 
discomfort and mild hematomas at venipuncture sites. Transient grade I 
hypotension (12%), grade I-II anemia (6%), hypokalemia (4%), and 1 urticarial 
eruption interpreted as a drug reaction to either 8- MOP or heparin were reported 
in a series of 51 patients [34]. In our study, adverse effects occurred in 2% of the 
performed sessions, of which, the most frequent complication was related to 
difficulties in venous access. The Deaths reported were not related to the 
treatment. 
The mean treatment volume was 161 ml (SD: 32), lower compared to reported in 
a single and dual-needle configuration [35]. The reduction in total treatment time 
from 2.18 to 1.47 hours that was observed when comparing peripheral and 
central venous access raises the need for appropriate implantable devices to 




ECP should be considered as first-line therapy for erythrodermic MF/SS based 
not only on its efficiency and excellent side effect profile but also on the 
significant improvement of the symptoms, particularly pruritus. The addition of 
adjunctive immunostimulatory agents may increase the response to ECP. 
Peripheral or central venous access procedure is feasible and with currently 
available closed systems, the risk of complications is very low. Further studies 
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Tables and Figures 
 
Table 1: Distribution of diagnosis by sex 
 Foliculotropic MF	 Hyperpigmented MF	 Sézary Syndrome 	 Total 	
 n	 % 	 n	 %	 n	 %	 n	 %	
Female	 3	 (42.9%)	 1	 (14.3%)	 3	 (42.9%)	 7	 (100.0%)	
Male	 3	 (30.0%)	 1	 (10.0%)	 6	 (60.0%)	 10	 (100.0%)	






































Table 2. Other population characteristics 
 Foliculotropic MF	 Hyperpigmented MF	 Sézary Syndrome 	
n	 6	 2	 9	
Male (%)	 3 (50%)	 1 (50%)	 6 (66.7%) 	
Contributive health 
system (%)	
4 (66.7%)  	 2 (100%) 	 7 (77.8%) 	
Education (%)	    
Elementary School	 1 (16.7%)	 2 (100%)	 1 (11%)	
Middle School	 0	 0	 1 (11%) 	
High School	 2 (33.3%)	 0	 0	
Technician	 0	 0	 2 (22.2%) 	
University Degree	 1(16.7%) 	 0	 3 (33.3%) 	
Master Degree	 0	 0	 1 (11.1%) 	
No data 	 2 (33.3%) 	 0	 1 (11.1%) 	
Origin (%)	    
Urban	 4 (66.7%)	 1 (50%) 	 8 (88.9%) 	












Table 3. T-cell receptor (TCR) gene rearrangements detected in skin and blood 
samples 
   TCR gene rearrangements detected in blood	






Negative	 1(33%) 	 0	 2 (66.7%) 	 3	
Positive	 0	 3 (50%)	 3 (50%) 	 6	
No data 	 0	 1(12.5%)	 7 (87.5%) 	 8	





































Table 4. ECP Treatment Characteristics discriminated by patient. Data of each 














1	 10	 2.18	 157.00	 2.56	 23.90	
2	 7	 2.30	 145.00	 2.40	 24.00	
3	 38	 2.29	 149.00	 2.48	 24.30	
4	 51	 2.22	 150.00	 2.50	 24.20	
5	 6	 2.23	 151.00	 2.52	 24.80	
6	 32	 2.02	 173.00	 2.89	 25.00	
7	 57	 2.22	 164.00	 2.71	 22.60	
8	 66	 2.18	 156.00	 2.60	 25.70	
9	 70	 2.07	 160.00	 2.66	 30.00	
10	 44	 2.21	 186.00	 3.12	 25.80	
11	 77	 2.23	 157.00	 2.63	 31.30	
12	 77	 2.05	 199.00	 3.33	 27.60	
13	 44	 1.98	 156.00	 2.62	 21.40	
14	 14	 2.23	 181.00	 3.07	 28.40	
15	 13	 1.34	 220.00	 3.68	 33.80	
16	 2	 2.09	 173.00	 2.90	 21.50	





















Table 5. Median reduction in mSWAT of the entire population after ECP 
treatment. 




mSWAT Last ECP	 80	 0-400	 92	



































Table 6. Median Reduction in VASP of the entire population after ECP treatment. 




VASP Last ECP	 6	 0-10	 96	




























































Figure 2. a) Differences in mean levels of Sézary´s Cells by Staging. b) Sézary´s 




















Figure 3. Systemic therapies received prior to the initiation of ECP. Other: 
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Figure 4. Number of ECP sessions received per patient. Green numbers 





















Figure 5. mSWAT changes discriminated by treatment response rates. CR: 



















Figure 6. VASP changes discriminated by treatment response rates. CR: 





















































Figure 8. Overall survival 
 
	
